.png)
.png)
From 1 January, an American physician who hears a patient say that something has felt wrong since their last vaccination will be able to bill Medicare for each additional fifteen minutes spent investigating. The code, G0576, was finalised on 4 November within the annual physician fee schedule. A British GP hearing the same sentence has no comparable payment mechanism and, in all likelihood, no spare time. The asymmetry looks small. It is the visible edge of a larger question about whom a vaccine-safety system answers to, and that question has reached Whitehall sooner than ministers would wish.
Robert F. Kennedy Jr., the US Health Secretary, presents the measure as overdue attention to people who have been dismissed. There is substance in that. Passive reporting systems undercount, and patients with genuine reactions often struggle to find a clinician with time for them. The difficulty lies in the surrounding architecture. Mr Kennedy has spent years asserting links between vaccines and harm, and his department has opened a vaccine injury clinic at the National Institutes of Health and will require electronic records to capture adverse events. It also initially promoted payment for reports to the Vaccine Adverse Event Reporting System. That database accepts submissions from anyone and cannot show that a vaccine caused anything. The final rule is silent on whether filing time is billable. Public health specialists fear that payment, data collection and conclusion now sit under one authority with a settled view.
Britain should not file this as a foreign curiosity, because its own arrangements carry weaknesses that an unfriendly reading could exploit. The Vaccine Damage Payment Scheme pays a one-off £120,000, a sum last revised in 2007, to people judged at least 60 per cent disabled by a vaccine, a test inherited from the 1979 Act and its roots in industrial injury assessment. Among Covid claims decided by the end of November 2024, fewer than two in a hundred were found eligible. The Covid Inquiry's report on vaccines, published in April, called for a payment that keeps pace with inflation and varies with the severity of injury. The government's response in October accepted that reform is needed and promised details in due course. It named no figure and no date.
That delay carries a cost the American episode makes plain. A grievance left to age does not disappear. It becomes available to anyone wishing to argue that officials do not care about the injured, and ministers have already accused some opposition MPs of promoting misinformation in Commons exchanges on the scheme. Washington shows how quickly such an argument can become policy once someone with authority adopts it. Britain has the grievance. What it lacks is a settled, generous and well-explained response to it.
The evidence of what is at stake is already in the figures. Between January and mid-August this year, laboratory testing confirmed 970 measles cases in England, which already exceeds the total for all of 2025, and two children have died of the disease. Only 84.4 per cent of children across the UK had received two doses of the vaccine by their fifth birthday in 2024-25, against a target of 95 per cent, and first-dose coverage in London stood at 72 per cent in April against 83 per cent in the South West. Integrated care boards now commission vaccination services and will be judged on uptake through the NHS Outcomes Framework. They will carry that duty into a climate in which a parent's doubt about safety meets a compensation scheme that the inquiry's chair found inadequately supportive.
For NHS leaders the practical task is to make the vaccine-injured visible to the service. Campaigners have asked for a clear care pathway for people with serious reactions, and the government has not yet committed to one. A pathway would give GPs a defined place to send patients and give the Yellow Card system a firmer base. The inquiry's call for linked primary and secondary care records for the Medicines and Healthcare products Regulatory Agency points the same way, since safety signals detected quickly by an independent regulator are harder to contest. Ministers should publish reform with numbers attached while the case can still be made from a position of competence. Life sciences companies, whose prospects depend on a regulator trusted at home and abroad, have reason to press for the same outcome in public.
Washington's policy will not travel to Britain by legislation. The argument behind it will arrive through social media and the testimony of people who feel ignored. The measure of a vaccine-safety system is whether an injured person is believed and helped by people with no stake in the answer. Britain can still meet that test on its own terms.